# Sequential Multiple Assignment Randomized Trial for COMparing Personalized Antibiotic Strategies (SMART COMPASS): Design Considerations


## Xiaoyan Yin, Toshimitsu Hamasaki, Scott R. Evans

The Biostatistics Center, The George Washington University


### Introduction – Background and Research Objectives

- A sequence of decisions with adjustment to therapy made over time in patients' management- Adjustments tailored to individual patients as new information about those patients becomes available
- Two therapeutic decision points in the treatment of serious bacterial infections
- **Empiric therapy** selected based on the clinicians' best judgment given the immediately available and often limited information upon recognition of the clinical syndrome
- **Definitive therapy** selected once organism identification, antibiotic susceptibility testing (AST) results, tolerability, and clinical course of the patient are known
- **SMART COMPASS:** a pragmatic design, mirroring antibiotic treatment decision-making as they unfold in clinical practice and addressing the most relevant question for treating patients: identification of the patient-management strategy that optimizes ultimate patient outcomes

### **Example of SMART COMPSS Deigns**




### Strategy #2 (S2)



### Example Hypotheses **Research Questions** (Contrast of Interest) Q1: Comparisons of empiric E1 is better than E2 under therapies coupled with AST=S (paths (a) vs. (d)) subsequent therapies: relevant Strategy #3 (S3) for clinicians triaging patients making empiric therapy decisions (+) without knowledge of definitive F1 therapy options and decisions. Population (-)Q2: Comparisons of definitive D1 is better than D2 Infection at Site X therapy conditioning on (paths (b) vs. (c)) empiric therapy: relevant E2 antibiotic drug developers as trials in the regulatory development paradigm comparing drugs Strategy #4 (S4) **Q3**: Pairwise S1 is better than S2 (+)**Comparisons of** strategy (paths (a)+(b) vs. (a)+(c)) E1 Population strategies: comparison relevant for S1>S2>S3>S4 (paths (a)+(b) Identification Infection clinicians planning at Site X of best vs. (a)+(c) vs. (d)+(e) vs. a sequential (+)(d)+(f))strategy clinical course of E2 treatment for patients

(+): S and tolerable; (-): Re or intolerable




Strategy Comparison	Parameter	arameter Hypothesis					
S1 vs. S2	$\delta_{12} = \mu_{S1} - \mu_{S2}$		$\hat{\delta}_{12} = \frac{\pi_1 \bar{Y}_1}{\pi}$				
S1 vs. S3	$\delta_{13} = \mu_{S1} - \mu_{S3}$		$\mathrm{H}_0:  \delta_{13} \leq 0 \; \mathrm{VS} \; \mathrm{H}_1:$	$\delta_{13} > 0$	$\hat{\delta}_{13} = \frac{\pi}{2}$		
Strategy Comparison	Test Statistic		$E[\hat{\delta}_{ij}]$				
S1 vs. S2	$Z_{12} = \frac{\hat{\delta}_{12}}{\operatorname{Var}[\hat{\delta}_{12}]}$	$\mathbf{E}[\hat{\delta}_{12}] = \frac{\pi}{2}$	$\frac{\pi_1 \mu_{10} + r_1 (1 - \pi_1) \mu_{11}}{\pi_1 + r_1 (1 - \pi_1)} - \frac{\pi_1 \mu_{11}}{\pi_1 + r_1 (1 - \pi_1)}$	$\frac{\mu_{10} + (1 - r_1)(1 - \pi_1)\mu_{12}}{\pi_1 + (1 - r_1)(1 - \pi_1)}$	$\operatorname{Var}[\hat{\delta}_{12}] = \hat{\delta}_{12}$		
S1 vs. S3	$Z_{13} = \frac{\hat{\delta}_{13}}{\operatorname{Var}[\hat{\delta}_{13}]}$	$\mathrm{E}[\hat{\delta}_{13}]$ :	$=\frac{\pi_1\mu_{10}+r_1(1-\pi_1)\mu_{11}}{\pi_1+r_1(1-\pi_1)}-\frac{\pi_1}{2}$	$\frac{\pi_2 \mu_{20} + r_2 (1 - \pi_2) \mu_{21}}{\pi_2 + r_2 (1 - \pi_2)}$	$\operatorname{Var}[\hat{\delta}_{13}] = \frac{\sigma^2}{n}$		
Strategy Comparison		N <sub>ij</sub>					
S1 vs. S2	$N_{12} = \begin{cases} N_{12}^* , \\ [N_{12}^*] + 1, \end{cases}$		if $N^*_{12}$ is integer, otherwise,	$N_{12}^* = \frac{\sigma^2 (z_{1-\alpha} + z_{1-\beta})^2}{(\delta_{12}^*)^2} \bigg\{ \frac{1}{r_0} \bigg\}$			
S1 vs. S3	$N_{13} = \begin{cases} N_{13}^* \\ [N_{13}] \end{cases}$	<sub>3</sub> , <sub>13</sub> ] + 1,	if $N^*_{13}$ is integer, otherwise,	$N_{13}^* = \frac{\sigma^2 (z_{1-\alpha} + z_{1-\alpha})}{(\delta_{13}^*)}$	$+ \frac{z_{1-\beta}}{2}^{2} \left\{ \frac{1}{r_{0}(\pi_{1})^{2}} \right\}$		
41	<b>. . . . . . . . . .</b>	·					

 $\mu_{Si}$ : the mean of the strategy *i*, and estimated by weighting the paths' sample means; i = 1, ..., 4;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii}^*$ : the clinically meaningful difference;  $\delta_{ii} = 1, ..., 4$ ;  $\delta_{ii} = 1, ..., 4$  $\mu_{Si} - \mu_{Si}$ ;  $i, j = 1, ..., 4, i \neq j$ ;  $N_{ij}$ : the total sample size required for the entire trial determined by the pairwise strategy comparison Si vs. Sj.

### **Procedure for Identifying the Best Strategy**

**Step 1**: Order the estimated mean values  $\hat{\mu}_{S(1)}$ ,  $\hat{\mu}_{S(2)}$ ,  $\hat{\mu}_{S(3)}$  and  $\hat{\mu}_{S(4)}$ , where  $\hat{\mu}_{S(4)} < \hat{\mu}_{S(3)} < \hat{\mu}_{S(2)} < \hat{\mu}_{S(1)}$ .

**Step 2**: Test each hypothesis with the order of  $H_{0(14)} \rightarrow$  $H_{0(13)} \rightarrow H_{0(12)}$  at the significance level of  $\alpha$  as long as significant results are observed in all preceding tests.



E1

E1

(a)

(a)

# Milken Institute School of Public Health

### THE GEORGE WASHINGTON UNIVERSITY


6110 Executive Blvd., Rockville, Maryland, 20852. Email xyin@bsc.gwu.edu

### Power and Sample Size Assessment via Simulation

$$\begin{split} \hat{\delta}_{ij} &= \hat{\mu}_{Si} - \hat{\mu}_{Sj} \\ \\ \frac{\bar{Y}_{10} + r_1(1 - \pi_1)\bar{Y}_{11}}{\pi_1 + r_1(1 - \pi_1)} - \frac{\pi_1\bar{Y}_{10} + (1 - r_1)(1 - \pi_1)\bar{Y}_{12}}{\pi_1 + (1 - r_1)(1 - \pi_1)} \\ \\ \frac{\pi_1\bar{Y}_{10} + r_1(1 - \pi_1)\bar{Y}_{11}}{\pi_1 + r_1(1 - \pi_1)} - \frac{\pi_2\bar{Y}_{20} + r_2(1 - \pi_2)\bar{Y}_{21}}{\pi_2 + r_2(1 - \pi_2)} \\ \\ &\quad \text{Var}[\hat{\delta}_{ij}] \\ \\ = \frac{\sigma^2}{n} \left\{ \frac{1 - \pi_1}{r_0(\pi_1 + r_1(1 - \pi_1))(\pi_1 + (1 - r_1)(1 - \pi_1))} \right\} \\ \\ \\ \frac{\sigma^2}{n} \left\{ \frac{1}{r_0(\pi_1 + r_1(1 - \pi_1))} + \frac{1}{(1 - r_0)(\pi_2 + r_2(1 - \pi_2))} \right\} \\ \\ \\ N_{ij}^* \\ \\ 1 - \pi_1 \end{pmatrix} \end{split}$$

$$\frac{1}{(\pi_1 + r_1(1 - \pi_1))(\pi_1 + (1 - r_1)(1 - \pi_1))}$$

$$\frac{1}{(1 + r_1(1 - \pi_1))} + \frac{1}{(1 - r_0)(\pi_2 + r_2(1 - \pi_2))}$$



$\pi_1$	<i>π</i> <sub>2</sub>	n	Marginal Power			Conditional Power	
			$\Pr[H_{1(12)}]$	$\Pr[H_{1(13)}]$	$\Pr[H_{1(14)}]$	$\Pr[H_{1(13)} H_{1(14)}]$	$\Pr[H_{1(12)} H_{1(13)}\cap H_{1(14)}]$
0.1	0.1	1352	0.801	>0.999	>0.999	>0.999	0.801
	0.5	1352	0.800	>0.999	>0.999	>0.999	0.800
	0.9	1351	0.801	>0.999	>0.999	>0.999	0.801
0.5	0.1	691	0.803	0.986	>0.999	0.986	0.800
	0.5	684	0.801	0.995	>0.999	0.995	0.800
	0.9	683	0.802	0.997	>0.999	0.997	0.800
0.9	0.1	299	0.999	0.819	0.990	0.816	0.800
	0.5	241	0.993	0.811	0.989	0.810	0.804
	0.9	217	0.980	0.813	0.990	0.812	0.800

 $r_0 = r_1 = r_2 = 0.5; \ \sigma^2 = 1; \ \mu_{10} = 1.0, \ \mu_{20} = 0.5, \ \mu_{S1} = 1.0, \ \mu_{S2} = 0.8, \ \mu_{S3} = 0.6 \text{ and } \ \mu_{S4} = 0.4. \\ \mu_{S(1)} = \mu_{S1}, \ \mu_{S(2)} = \mu_{S2}, \ \mu_{S(3)} = \mu_{S3} \text{ and } \ \mu_{S(4)} = \mu_{S4}, \ \mu_{S4$ and  $\delta_{(12)} = \delta_{12} = 0.2$ ,  $\delta_{(13)} = \delta_{13} = 0.4$  and  $\delta_{(14)} = \delta_{14} = 0.6$ .

### Findings from Simulations

- For pairwise comparisons, when comparing S1 and S2, the required sample size  $N_{12}$  increases as  $\pi_1$  goes to zero, but is unaffected by  $\pi_2 \leftarrow$  less "shared" participants (smaller  $\pi_1$ ) decrease size of variance of  $\hat{\delta}_{12}$ .
- When comparing S1 with S3, the required sample size  $N_{13}$  increases as  $\pi_1$  and/or  $\pi_2$  go to zero  $\leftarrow$  the size of variance for  $\hat{\delta}_{13}$  becomes larger with smaller  $\pi_1$  and/or  $\pi_2$ .
- If  $\pi_1$  is less than 0.6, the power to detect  $\delta_{(12)}$  is smaller than that for  $\delta_{(13)}$ .
- For identify the best strategy, the required sample size n gradually deceases with higher  $\pi_1$ . Under the fixed  $\pi_1$ , n tends to be smaller with larger values of  $\pi_2$ . This tendency becomes clearer with higher  $\pi_1$ .



## THE BIOSTATISTICS CENTER